Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment by Maltezou, Helena C & Papa, Anna
COMMENTARY Open Access
Crimean-Congo hemorrhagic fever: epidemiological
trends and controversies in treatment
Helena C Maltezou
1* and Anna Papa
2
Abstract
Crimean-Congo hemorrhagic fever (CCHF) virus has
the widest geographic range of all tick-borne viruses
and is endemic in more than 30 countries in Eurasia
and Africa. Over the past decade, new foci have
emerged or re-emerged in the Balkans and
neighboring areas. Here we discuss the factors
influencing CCHF incidence and focus on the main
issue of the use of ribavirin for treating this infection.
Given the dynamics of CCHF emergence in the past
decade, development of new anti-viral drugs and a
vaccine is urgently needed to treat and prevent this
acute, life-threatening disease.
Background
Crimean-Congo hemorrhagic fever (CCHF) is an acute,
highly-contagious and life-threatening disease caused by a
nairovirus of the Bunyaviridae family [1-3]. CCHF was
probably described by a physician in Tajikistan in 1100 AD
in a patient with hemorrhagic manifestations [2]. In recent
times, the disease was first recognized during an outbreak
in Crimea in 1944, however, later it became evident that
the causative agent was identical to a virus isolated from a
patient in Congo in 1956, and the name CCHF was
adopted [4]. CCHF virus (CCHFV) circulates in nature in a
tick-vertebrate-tick cycle, mainly among cattle, sheep,
goats, and hares. The infection is transmitted to humans
primarily by ticks of the genus Hyalomma,b u ta l s o
through direct contact with blood or tissues of viremic
patients or animals [1,2]. Typical CCHF progresses rapidly
with high fever, malaise, severe headache, and gastrointest-
inal symptoms. CCHF is confirmed either by detection of
specific immunoglobulin M antibodies or a four-fold
increase of immunoglobulin G titers using enzyme-linked
immunoassays, indirect immunofluorescent assays, or
through reverse transcriptase-polymerase chain reaction
and microarray techniques [1,5,6]. Prominent hemorrhages
may occur at a late stage of disease, with case fatality rates
ranging from 5% to 50%. CCHF is a disease of immediate
notification to public health authorities because of the
potential of nosocomial outbreaks [7-10] and use in bioter-
rorism [11].
CCHFV has the widest geographic range among all tick-
borne viruses, being endemic in more than 30 countries in
Eurasia and Africa [1,5]. CCHF activity has increased over
the past decade and new foci have emerged in several Bal-
kan countries, as well as in neighboring areas (Figure 1)
[5,8,12-15]. In a serosurvey conducted in Northeastern
Greece after the first human case occurred in June 2008,
seroprevalence rates up to 5% were found in well-confined
areas compared with 0% found in the same areas 20 years
ago [16], suggesting recent introduction of the virus. After
almost three decades, CCHF re-emerged in southwest
Russia in 1999, with hundreds of cases being reported
since then [17]. An essential factor of the CCHF re-emer-
g e n c ei nR u s s i aw a sar i s ei nt h en u m b e ro fHyalomma
marginatum ticks [18]. Enzootic circulation of the
CCHFV was documented in Turkey for several decades,
however the first human cases occurred in 2002; since
then, Turkey has experienced the largest ever recorded
CCHF outbreak with more than 4,400 confirmed cases,
mainly from rural areas in Northeast Anatolia [19]. At the
epicenter of this outbreak, the seroprevalence rate was
12.8% among high-risk groups [20]. Recently, 26 cases
were identified in western Turkey [21], indicating further
spread towards the west in this country, which is attribu-
ted to the vegetation fragmentation in this area, as well as
in Anatolia, in association with increased awareness of this
disease following the 2006 campaign [21]. This article dis-
cusses factors influencing CCHF incidence and focuses on
the main issue at stake: the use of ribavirin for treatment.
Factors influencing CCHF incidence
As for all vector-borne diseases, environmental factors,
climate, and human behaviour are critical determinants
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micity within an area. However, although explanations
about CCHF emergence or re-emergence have been for-
mulated [5,17,22-24], the contribution of each of these
factors has not been quantified so far.
Humans may modify the risk of CCHFV transmission
through changes in land use, recreational activities, and
livestock movement [5], and increasing awareness may
also impact the incidence of CCHF [21], whereas limita-
tions in diagnostic capacities and surveillance may ham-
per the estimation of CCHF burden in several endemic
areas [17].
Hyalomma ticks favor dry climates and arid-type vegeta-
tion, and are abundant in European countries bordering
the Mediterranean Sea, along with numerous animals
which may act as CCHFV hosts [12]. However, their
established presence does not ensure CCHF expansion to
these areas per se. Besides most Balkan countries, which
are well-known to be endemic for the presence of CCHF
for several decades, serologic evidence of CCHF is scantily
available elsewhere in Europe [12,25,26]. Introduction of
CCHFV to a non-endemic area could happen either
through legal or illegal trade of infected animals or animals
infested with infected ticks or through geographic expan-
sion of infected Hyalomma ticks from CCHF-endemic to
CCHF-naive areas [27,28].
A model investigating the impact of several climate sce-
narios on ticks, has found that a rise in temperature and
decrease in rainfall in the Mediterranean region could
result in a sharp rise of the distribution of suitable habitat
for Hyalomma ticks northwards, with the highest impact
at the boundaries of their current range [29]. CCHFV
infected animals only experience viremia for a few days,
which is likely an intrinsic limit for the establishment of
successive transmission cycles after their importation,
beyond the onset of a localized outbreak [12]. CCHFV ser-
oprevalence rates among animals are good predictors of
human risk for infection [14]. Given the dynamics of
CCHF over the past decade, further studies on ticks and
animals will allow the detection of presumed unaffected
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Figure 1 Foci of CCHF emergence or re-emergence in southeast Europe and neighboring countries from 2000. Stars indicate sites of
CCHF emergence in southeastern Europe; oval indicates the epicenter of the large CCHF epidemic in Northeastern Anatolia, Turkey; and circles
indicate the site of CCHF re-emergence in Southwestern Russia (Data from References 12 and 17). The Figure was created based on a map
outline available at: http://geography.about.com/library/blank/blxeurope.htm. Abbreviations: CCHF, Crimean-Congo hemorrhagic fever.
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emergence [22,23], with the highest risk in neighboring
areas to those with established endemicity.
Control strategies
Given that the control of ticks is an unrealistic goal [30],
strategies should focus on enhancing surveillance using
standardized case definitions [31], and increasing labora-
tory capacity within already endemic areas and areas at
risk for CCHF expansion [17]. The general population
and health-care workers should be aware of prophylactic
measures and modify their risk for infection.
An inactivated suckling mouse brain vaccine was devel-
oped in the former Soviet Union in the late 1960’s with no
adverse effects recorded on the limited number of volun-
teers [30]. Data from approximately 2,000 healthy persons
vaccinated in 1970 indicated that neutralizing CCHFV
antibodies developed 1 to 4 weeks after the third shot, but
titers decreased 3 to 6 months later [30]. The vaccine has
been used for high risk groups in Bulgaria since 1974.
Although surveillance data suggest a four-fold reduction
in the number of notified CCHF cases in Bulgaria after the
introduction of vaccination, data regarding vaccine efficacy
have not been published [30]. Recently, the CCHFV strain
which is used for vaccine preparation was genetically char-
acterized, providing the basis for further studies [32].
Overall, there are concerns about using mouse brain vac-
cines because of possible autoimmune responses. CCHF is
mainly confined to poor resource countries, and research
has been extremely slow. A humanized vaccine against
CCHF is needed, however long-term in-field studies will
be required to show efficacy.
Issues of treatment and prophylaxis
To date only ribavirin, a broad anti-RNA virus inhibitor,
demonstrates in vitro activity against CCHFV either in cell
culture [33,34], or in mice models [35,36]. In the historical
study conducted by Mardani et al. in Iran during 1999-
2001, the case fatality rate was 11.6% (8 of 69 patients) in
the group treated with oral ribavirin compared with 58.3%
(7 of 12 patients) in the untreated group, which corre-
sponded to 80% efficacy (P < 0.001) [37]. This study con-
stituted the basis for the World Health Organization
(WHO) recommendations for treating CCHF patients
with ribavirin. Promising results were also reported by
others, and were mainly associated with early treatment
[38-40]. However, the use of ribavirin for CCHF treatment
remains an issue of controversy since no difference in case
fatality rates was found in other studies [41-43], including
the only randomized controll e dt r i a lp u b l i s h e do nt h i s
topic so far (6.3% among 64 ribavirin-treated patients ver-
sus 5.6% among 72 untreated patients; P = 0.86) [42].
Almost all data about ribavirin efficacy are limited to small
observational studies and case series, and questions about
methodological issues have been raised (for example no
control for disease severity or day of initiation of treat-
ment) [17]. In a recent meta-analysis of 21 studies asses-
sing the efficacy of ribavirin on CCHF outcome, the
authors concluded that current evidence is insufficient to
provide a clear answer [44]. Currently, ribavirin is used in
most endemic countries [17], and ethical issues about
using a placebo-control group have been raised. Given the
high fatality rates associated with CCHF, a well-designed
multi-center, randomized controlled trial taking into
account severity criteria is urgently needed in order to
provide evidence-based data about ribavirin efficacy.
Recombinant and natural interferons-a exhibit activity
against CCHFV in vitro, and might prove a promising
treatment approach in the very early course of illness or
as post-exposure prophylaxis, however no human studies
have been conducted yet [45]. The MxA protein, an
interferon-induced protein of the superfamily of large
GTPases, is a key component in the interferon-induced
inhibition of replication of several viruses, including
CCHFV [46]. There are data suggesting that CCHFV
possesses mechanisms to defeat the interferon-induced
defense mechanisms by delaying IFN secretion for 48
hours post-infection [47]. This may allow the rapid pro-
gression of illness rendering the infection almost IFN-
insensitive, a phenomenon that may be linked to its
pathogenicity [47]. Specific laboratory findings may serve
as prognostic factors for severe disease (for example
severe thrombocytopenia, elevated transaminases, pro-
longed aPTT (activated partial thromboplastin time),
decreased fibrinogen) with viral load and levels of specific
cytokines playing an important factor affecting the course
and the outcome of the disease [24,45,48-51]. These fac-
t o r sm a yb eu s e f u la sc r i t e r i af o rt h ec o n s t r u c t i o no fa n
algorithm about whether and when antiviral medications
should be given.
Conclusions
CCHF is a disease of public health importance with a
high fatality rate that has risen in incidence and displayed
geographical spread over the past decade. However, to
date, the driving forces behind this spread and increase
in incidence remain unclear. Given this, it would be
worth identifying areas at risk for CCHF and enhance
surveillance. Development of new therapies and an effec-
tive and safe vaccine against CCHF would also contribute
to keep CCHF under control.
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